1.Gorusu M., Benn P., Li Z., Fang M. On the genesis and prognosis of variant translocations in chronic myeloid leukemia. Cancer Genet Cytogenet. 2007. 173:97–106.
Article
2.So CC., Wan TS., Yip SF., Chan LC. A dual colour dual fusion fluorescence in situ hybridisation study on the genesis of complex variant translocations in chronic myelogenous leukaemia. Oncol Rep. 2008. 19:1181–4.
Article
3.Richebourg S., Eclache V., Perot C., Portnoi MF., Van den Akker J., Terré C, et al. Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy. Cancer Genet Cytogenet. 2008. 182:95–102.
4.Bennour A., Sennana H., Laatiri MA., Elloumi M., Khelif A., Saad A. Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9. Cancer Genet Cytogenet. 2009. 194:30–7.
Article
5.Mark HF., Sokolic RA., Mark Y. Conventional cytogenetics and FISH in the detection of BCR/ABL fusion in chronic myeloid leukemia (CML). Exp Mol Pathol. 2006. 81:1–7.
6.Shaffer LG., Slovak ML, et al. eds. ISCN. 2009. an international system for human cytogenetic nomenclature (2009). Basel: Karger, 2009.
7.O'Brien S., Thall PF., Siciliano MJ. Cytogenetics of chronic myelogenous leukaemia. Baillieres Clin Haematol. 1997. 10:259–76.
8.El-Zimaity MM., Kantarjian H., Talpaz M., O'Brien S., Giles F., Garcia-Manero G, et al. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol. 2004. 125:187–95.
Article
9.Johansson B., Fioretos T., Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002. 107:76–94.
Article
10.Sandberg AA. Chromosomes and causation of human cancer and leukemia: XL. The Ph1 and other translocations in CML. Cancer. 1980. 46:2221–6.
Article
11.Loncarevic IF., Romer J., Starke H., Heller A., Bleck C., Ziegler M, et al. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia. Genes Chromosomes Cancer. 2002. 34:193–200.
12.Reid AG., Huntly BJ., Grace C., Green AR., Nacheva EP. Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol. 2003. 121:419–27.
Article
13.Yuregir OO., Sahin FI., Yilmaz Z., Kizilkilic E., Karakus S., Ozdogu H. Fluorescent in situ hybridization studies in multiple myeloma. Hematology. 2009. 14:90–4.
14.Chen L., Li J., Xu W., Qiu H., Zhu Y., Zhang Y, et al. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization. Exp Oncol. 2007. 29:116–20.